SignaLife · raw details

Non-invasive Continuous Blood Gas and pH Sensor · Tel Aviv-Yafo · Founded 2021

active Pre-Seed ← back to profile

Highlights

IIA supported (ever)1 patentProfile claimed by owner

About

Non-invasive Continuous Blood Gas and pH Sensor

SignaLife is a technology company developing lifesaving AI optic sensors for medical and well-being use. The company’s products are designed to provide non-invasive and continuous pH and Blood Gases for patients hospitalized in the ICU and NICU (neonatal ICU).

Initial results from the company’s first in human trial in Assuta Ashdod ICU, showing high accuracy in testing pH, pCO2, Bi-carbonate (HCO3) and lactate. First baby in the 2nd clinical trial in Sheba Medical Center’s NICU was recruited during April 2025 with promising pH results.

SignaLife’s solutions address the need for non-invasive, reliable measurements, reducing infection risk, minimizing blood draws, and supporting better treatment decisions.

Identity

NameSignaLife
Slugsignalife
Type / kindstartup
Source _idWrYQtiYAgQT7QBsMgZMjtyu1LullDnRkEgeWEgzKl3KE4eJPpUdsQM

Status

Statusactive
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtCenter District
HQ cityTel Aviv-Yafo
HQ addressBareli St 12, Tel Aviv-Yafo, Israel

Web & social

Websitehttps://www.signalife.com/
LinkedInhttps://www.linkedin.com/company/101222372/

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Monitors
Technologies
Artificial IntelligenceSensing
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B
Tags
medical-devicesmonitoring

Funding

Total raised$2.7M
Current stagePre-Seed

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}